News | April 27, 2010

Key Trial Data Explained at SCAI's Annual Meeting

The Society for Cardiovascular Angiography and Interventions’ (SCAI) upcoming 33rd Annual Scientific Sessions promises the latest news in interventional cardiology from leading experts in the field. The event will take place May 5-8 in San Diego.

This year’s meeting will feature a late-breaking clinical trial surrounding two-year interim results from the single-arm study of the Zilver PTX drug-eluting peripheral stent. William Gray, M.D., will present the data at 11:30 a.m. Pacific time on Friday, May 7.

Additionally, the following notable abstracts will be presented at the meeting:

• One-year results from the EVEREST II High Risk Registry, which examines the safety and efficacy of the transcatheter MitraClip Therapy in relieving symptoms for patients with mitral regurgitation.

• Safety and efficacy data from the ARMOUR trial — a pivotal, prospective, multicenter, nonrandomized trial to evaluate the safety and effectiveness of cerebral protection with the Mo.Ma embolic protection device in high surgical risk subjects undergoing carotid artery stenting (CAS).

• Early findings from the first clinical human study designed to investigate an implantable ST-segment monitoring system that detects and alerts patients to coronary plaque rupture and ischemia.

• Results surrounding the impact of a seven day, 24-hour in-hospital cardiac catheterization lab program on door-to-balloon time in patients presenting with ST-elevated myocardial infarction (STEMI) during off verses regular hours.

• Retrospective review of patients undergoing percutaneous coronary intervention (PCI) and same-day discharge, compared for their appropriateness under the 2009 the American College of Cardiology/American Heart Association/SCAI guidelines on outpatient PCI.

• Hypotheses surrounding the low rate of adoption of transradial access (TRA) for cardiac catheterization in the United States.

Other meeting highlights include a session surrounding practice survival in the era of health care reform, led by Gregory J. Dehmer, M.D., and Edward T. Fry, M.D. Keynote addresses will cover the influence of comparative effectiveness on interventional cardiology; the past, present, and future of stent treatment for congenital heart disease; and a historical perspective of the early days of coronary intervention.

The inauguration of Larry S. Dean, M.D., FSCAI, FACC, FAHA as 33rd president of SCAI will also take place during the annual meeting. Dean recently played an integral role in communicating concerns to the Washington State Health Technology Assessment Committee regarding its proposal to restrict coverage of drug-eluting stents for state-insured employees and Medicaid beneficiaries.

For more information:

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init